Literature DB >> 18166484

Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo.

Eileen M Denovan-Wright1, Edgardo Rodriguez-Lebron, Alfred S Lewin, Ronald J Mandel.   

Abstract

Gene transfer strategies to reduce levels of mutant huntingtin (mHtt) mRNA and protein by targeting human Htt have shown therapeutic promise in vivo. Previously, we have reported that a specific, adeno-associated viral vector (rAAV)-delivered short-hairpin RNA (siHUNT-2) targeting human Htt mRNA unexpectedly decreased levels of striatal-specific transcripts in both wild-type and R6/1 transgenic HD mice. The goal of this study was to determine whether the siHUNT-2-mediated effect was due to adverse effects of RNA interference (RNAi) expression in the brain. To this end, we designed two catalytically active hammerhead ribozymes directed against the same region of human Htt mRNA targeted by siHUNT-2 and delivered them to wild-type and R6/1 transgenic HD mice. After 10 weeks of continuous expression, these ribozymes, like siHUNT-2, negatively impacted the expression of a subset of genes in the striatum. This effect was independent of rAAV transduction and specific to the targeting of a unique sequence in human Htt mRNA. After consideration of the known potential RNAi-specific toxic mechanisms, only cleavage of an unintended RNA target can account for the data reported herein. Thus, long-term rAAV-mediated RNAi in the brain does not, in and of itself, negatively affect striatal gene expression. These findings have important implications in the development of therapeutic RNAi for the treatment of neurological disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18166484      PMCID: PMC2695881          DOI: 10.1016/j.nbd.2007.11.003

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  45 in total

1.  Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice.

Authors:  J A Bibb; Z Yan; P Svenningsson; G L Snyder; V A Pieribone; A Horiuchi; A C Nairn; A Messer; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Expression profiling reveals off-target gene regulation by RNAi.

Authors:  Aimee L Jackson; Steven R Bartz; Janell Schelter; Sumire V Kobayashi; Julja Burchard; Mao Mao; Bin Li; Guy Cavet; Peter S Linsley
Journal:  Nat Biotechnol       Date:  2003-05-18       Impact factor: 54.908

3.  Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase.

Authors:  Dong-Ho Kim; Michael Longo; Young Han; Patric Lundberg; Edouard Cantin; John J Rossi
Journal:  Nat Biotechnol       Date:  2004-02-08       Impact factor: 54.908

4.  Chemical and enzymatic probing of effector-mediated changes in the conformation of a maxizyme.

Authors:  J M Zhou; Y Nakamatsu; T Kuwabara; M Warashina; Y Tanaka; K Yoshinari; K Taira
Journal:  J Inorg Biochem       Date:  2000-03       Impact factor: 4.155

5.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.

Authors:  M Chen; V O Ona; M Li; R J Ferrante; K B Fink; S Zhu; J Bian; L Guo; L A Farrell; S M Hersch; W Hobbs; J P Vonsattel; J H Cha; R M Friedlander
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

Review 6.  Transcriptional abnormalities in Huntington disease.

Authors:  Katharine L Sugars; David C Rubinsztein
Journal:  Trends Genet       Date:  2003-05       Impact factor: 11.639

7.  Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.

Authors:  Robert J Ferrante; James K Kubilus; Junghee Lee; Hoon Ryu; Ayshe Beesen; Birgit Zucker; Karen Smith; Neil W Kowall; Rajiv R Ratan; Ruth Luthi-Carter; Steven M Hersch
Journal:  J Neurosci       Date:  2003-10-15       Impact factor: 6.167

8.  Activation of the interferon system by short-interfering RNAs.

Authors:  Carol A Sledz; Michelle Holko; Michael J de Veer; Robert H Silverman; Bryan R G Williams
Journal:  Nat Cell Biol       Date:  2003-08-24       Impact factor: 28.824

9.  Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.

Authors:  A L O Hebb; H A Robertson; E M Denovan-Wright
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

Review 10.  Huntingtin-protein interactions and the pathogenesis of Huntington's disease.

Authors:  Shi-Hua Li; Xiao-Jiang Li
Journal:  Trends Genet       Date:  2004-03       Impact factor: 11.639

View more
  7 in total

1.  Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

Authors:  Holly B Kordasiewicz; Lisa M Stanek; Edward V Wancewicz; Curt Mazur; Melissa M McAlonis; Kimberly A Pytel; Jonathan W Artates; Andreas Weiss; Seng H Cheng; Lamya S Shihabuddin; Gene Hung; C Frank Bennett; Don W Cleveland
Journal:  Neuron       Date:  2012-06-21       Impact factor: 17.173

Review 2.  Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics.

Authors:  Marc S Weinberg; Matthew J A Wood
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

3.  Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons.

Authors:  Ayse Ulusoy; Gurdal Sahin; Tomas Björklund; Patrick Aebischer; Deniz Kirik
Journal:  Mol Ther       Date:  2009-07-07       Impact factor: 11.454

Review 4.  Emerging Therapies for Huntington's Disease - Focus on N-Terminal Huntingtin and Huntingtin Exon 1.

Authors:  M Leontien van der Bent; Melvin M Evers; Astrid Vallès
Journal:  Biologics       Date:  2022-09-30

Review 5.  Huntington's disease: silencing a brutal killer.

Authors:  Edith L Pfister; Phillip D Zamore
Journal:  Exp Neurol       Date:  2009-09-25       Impact factor: 5.330

Review 6.  Gene suppression approaches to neurodegeneration.

Authors:  Rhia Ghosh; Sarah J Tabrizi
Journal:  Alzheimers Res Ther       Date:  2017-10-05       Impact factor: 6.982

Review 7.  Delivery systems and local administration routes for therapeutic siRNA.

Authors:  Fabiana Testa Moura de Carvalho Vicentini; Lívia Neves Borgheti-Cardoso; Lívia Vieira Depieri; Danielle de Macedo Mano; Thais Fedatto Abelha; Raquel Petrilli; Maria Vitória Lopes Badra Bentley
Journal:  Pharm Res       Date:  2013-01-24       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.